Panitumumab monotherapy for gemcitabine, TS-1 and CDDP tolerant or failure unresectable or recurrent cholangiocarcinoma, evaluation of safety and efficiency.

Trial Profile

Panitumumab monotherapy for gemcitabine, TS-1 and CDDP tolerant or failure unresectable or recurrent cholangiocarcinoma, evaluation of safety and efficiency.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Apr 2014

At a glance

  • Drugs Panitumumab (Primary)
  • Indications Cholangiocarcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Oct 2011 Actual initiation date changed from Sep 2011 to Apr 2012 as reported by University Hospital Medical Information Network - Japan.
    • 05 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top